Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The
investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy
adult male volunteers, comparing a group in whom SAP has been completely depleted at the time
of DNA vaccination and a control group vaccinated without SAP depletion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University College, London
Collaborators:
GlaxoSmithKline Medical Research Council University of Oxford